Table 5 Characteristics of patients deceased during rituximab treatment and up to 12Â months after treatment discontinuation
Rituximab indication | Gender | Charlson comorbidity index | Age at first rituximab, years | Treatment duration, years | Time from last rituximab to death, days | Cause of death |
|---|---|---|---|---|---|---|
RA | F | 5 | 48 | 2.8 | 63 | Pulmonary aspergillosis |
RA | M | 0 | 75 | 9.7 | 62 | Pneumocystis jirovecii pneumonia |
RA | M | 2 | 81 | 1.2 | 179 | Sepsis secondary to pulmonary aspergillosis and haemorrhagic shock secondary to bleeding duodenal ulcer |
RA | F | 9 | 61 | 0.04 | 189 | Lung cancer |
SLE | F | 5 | 34 | 1.4 | 41 | Miliary tuberculosis |
MCTD | F | 1 | 49 | 6.2 | 60 | Progressive multifocal leukoencephalopathy |
GPA | M | 4 | 63 | 2.9 | 221 | Unknown |
Hepatitis C-associated cryoglobulinemic vasculitis | F | 6 | 85 | 0.02 | 9 | Hepatic and renal failure |
Hepatitis C-associated cryoglobulinemic vasculitis | M | 5 | 77 | 6.4 | 128 | Sepsis due to Escherichia coli |
Interstitial lung disease | M | 4 | 62 | 0.04 | 152 | Unknown |